Selected research
Market Structure
Global Anti-Asthma Short Acting Beta Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-Asthma Short Acting Beta Agonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Anti-Asthma Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-Asthma Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-Asthma Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-Asthma Short Acting Beta Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-Asthma Short Acting Beta Agonists include Chia Tai Tianqing Pharmaceutical Group, Teva Pharmaceutical, Sichuan Puretech Pharmaceutical, Sanofi, Novartis, Shandong Lunan Pharmaceutical, Joincare Pharmaceutical Group Industry, Pfizer and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Anti-Asthma Short Acting Beta Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-Asthma Short Acting Beta Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-Asthma Short Acting Beta Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Asthma Short Acting Beta Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-Asthma Short Acting Beta Agonists Segment by Company
Chia Tai Tianqing Pharmaceutical Group
Teva Pharmaceutical
Sichuan Puretech Pharmaceutical
Sanofi
Novartis
Shandong Lunan Pharmaceutical
Joincare Pharmaceutical Group Industry
Pfizer
Jiangsu Hengrui Pharmaceuticals
GlaxoSmithKline
AstraZeneca
Viatris
Boehringer Ingelheim
Anti-Asthma Short Acting Beta Agonists Segment by Type
Non-Selective Beta Receptor Agonists
Selective Beta 2 Receptor Agonists
Anti-Asthma Short Acting Beta Agonists Segment by Application
Pharmacy
Hospital
Clinic
Others
Anti-Asthma Short Acting Beta Agonists Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Asthma Short Acting Beta Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Asthma Short Acting Beta Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Asthma Short Acting Beta Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-Asthma Short Acting Beta Agonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Asthma Short Acting Beta Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-Asthma Short Acting Beta Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-Asthma Short Acting Beta Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Non-Selective Beta Receptor Agonists
- Selective Beta 2 Receptor Agonists
Applications
- Pharmacy
- Hospital
- Clinic
- Others
Companies covered
- Chia Tai Tianqing Pharmaceutical Group
- Teva Pharmaceutical
- Sichuan Puretech Pharmaceutical
- Sanofi
- Novartis
- Shandong Lunan Pharmaceutical
- Joincare Pharmaceutical Group Industry
- Pfizer
- Jiangsu Hengrui Pharmaceuticals
- GlaxoSmithKline
- AstraZeneca
- Viatris
- Boehringer Ingelheim
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-Asthma Short Acting Beta Agonists Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-Asthma Short Acting Beta Agonists Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Anti-Asthma Short Acting Beta Agonists Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Anti-Asthma Short Acting Beta Agonists Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Anti-Asthma Short Acting Beta Agonists Market Dynamics
- 2.1 Anti-Asthma Short Acting Beta Agonists Industry Trends
- 2.2 Anti-Asthma Short Acting Beta Agonists Industry Drivers
- 2.3 Anti-Asthma Short Acting Beta Agonists Industry Opportunities and Challenges
- 2.4 Anti-Asthma Short Acting Beta Agonists Industry Restraints
3 Anti-Asthma Short Acting Beta Agonists Market by Manufacturers
- 3.1 Global Anti-Asthma Short Acting Beta Agonists Revenue by Manufacturers (2021-2026)
- 3.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Manufacturers (2021-2026)
- 3.3 Global Anti-Asthma Short Acting Beta Agonists Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Anti-Asthma Short Acting Beta Agonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-Asthma Short Acting Beta Agonists Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-Asthma Short Acting Beta Agonists Manufacturers, Product Type & Application
- 3.7 Global Anti-Asthma Short Acting Beta Agonists Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-Asthma Short Acting Beta Agonists Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-Asthma Short Acting Beta Agonists Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-Asthma Short Acting Beta Agonists Tier 1, Tier 2, and Tier 3
4 Anti-Asthma Short Acting Beta Agonists Market by Type
- 4.1 Anti-Asthma Short Acting Beta Agonists Type Introduction
- 4.1.1 Non-Selective Beta Receptor Agonists
- 4.1.2 Selective Beta 2 Receptor Agonists
- 4.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Type
- 4.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Type (2021-2032)
- 4.2.3 Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Type (2021-2032)
- 4.3 Global Anti-Asthma Short Acting Beta Agonists Revenue by Type
- 4.3.1 Global Anti-Asthma Short Acting Beta Agonists Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-Asthma Short Acting Beta Agonists Revenue by Type (2021-2032)
- 4.3.3 Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Type (2021-2032)
5 Anti-Asthma Short Acting Beta Agonists Market by Application
- 5.1 Anti-Asthma Short Acting Beta Agonists Application Introduction
- 5.1.1 Pharmacy
- 5.1.2 Hospital
- 5.1.3 Clinic
- 5.1.4 Others
- 5.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Application
- 5.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Application (2021-2032)
- 5.2.3 Global Anti-Asthma Short Acting Beta Agonists Sales Market Share by Application (2021-2032)
- 5.3 Global Anti-Asthma Short Acting Beta Agonists Revenue by Application
- 5.3.1 Global Anti-Asthma Short Acting Beta Agonists Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-Asthma Short Acting Beta Agonists Revenue by Application (2021-2032)
- 5.3.3 Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Application (2021-2032)
6 Global Anti-Asthma Short Acting Beta Agonists Sales by Region
- 6.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-Asthma Short Acting Beta Agonists Sales by Region (2021-2032)
- 6.2.1 Global Anti-Asthma Short Acting Beta Agonists Sales by Region (2021-2026)
- 6.2.2 Global Anti-Asthma Short Acting Beta Agonists Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-Asthma Short Acting Beta Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-Asthma Short Acting Beta Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-Asthma Short Acting Beta Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-Asthma Short Acting Beta Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Anti-Asthma Short Acting Beta Agonists Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Anti-Asthma Short Acting Beta Agonists Revenue by Region
- 7.1 Global Anti-Asthma Short Acting Beta Agonists Revenue by Region
- 7.1.1 Global Anti-Asthma Short Acting Beta Agonists Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Anti-Asthma Short Acting Beta Agonists Revenue by Region (2021-2026)
- 7.1.3 Global Anti-Asthma Short Acting Beta Agonists Revenue by Region (2027-2032)
- 7.1.4 Global Anti-Asthma Short Acting Beta Agonists Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Anti-Asthma Short Acting Beta Agonists Revenue (2021-2032)
- 7.2.2 North America Anti-Asthma Short Acting Beta Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Anti-Asthma Short Acting Beta Agonists Revenue (2021-2032)
- 7.3.2 Europe Anti-Asthma Short Acting Beta Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-Asthma Short Acting Beta Agonists Revenue (2021-2032)
- 7.4.2 Asia-Pacific Anti-Asthma Short Acting Beta Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-Asthma Short Acting Beta Agonists Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Anti-Asthma Short Acting Beta Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Chia Tai Tianqing Pharmaceutical Group
- 8.1.1 Chia Tai Tianqing Pharmaceutical Group Company Information
- 8.1.2 Chia Tai Tianqing Pharmaceutical Group Business Overview
- 8.1.3 Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Chia Tai Tianqing Pharmaceutical Group Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.1.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments
- 8.2 Teva Pharmaceutical
- 8.2.1 Teva Pharmaceutical Company Information
- 8.2.2 Teva Pharmaceutical Business Overview
- 8.2.3 Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Teva Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.2.5 Teva Pharmaceutical Recent Developments
- 8.3 Sichuan Puretech Pharmaceutical
- 8.3.1 Sichuan Puretech Pharmaceutical Company Information
- 8.3.2 Sichuan Puretech Pharmaceutical Business Overview
- 8.3.3 Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sichuan Puretech Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.3.5 Sichuan Puretech Pharmaceutical Recent Developments
- 8.4 Sanofi
- 8.4.1 Sanofi Company Information
- 8.4.2 Sanofi Business Overview
- 8.4.3 Sanofi Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sanofi Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.4.5 Sanofi Recent Developments
- 8.5 Novartis
- 8.5.1 Novartis Company Information
- 8.5.2 Novartis Business Overview
- 8.5.3 Novartis Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Novartis Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.5.5 Novartis Recent Developments
- 8.6 Shandong Lunan Pharmaceutical
- 8.6.1 Shandong Lunan Pharmaceutical Company Information
- 8.6.2 Shandong Lunan Pharmaceutical Business Overview
- 8.6.3 Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Shandong Lunan Pharmaceutical Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.6.5 Shandong Lunan Pharmaceutical Recent Developments
- 8.7 Joincare Pharmaceutical Group Industry
- 8.7.1 Joincare Pharmaceutical Group Industry Company Information
- 8.7.2 Joincare Pharmaceutical Group Industry Business Overview
- 8.7.3 Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Joincare Pharmaceutical Group Industry Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.7.5 Joincare Pharmaceutical Group Industry Recent Developments
- 8.8 Pfizer
- 8.8.1 Pfizer Company Information
- 8.8.2 Pfizer Business Overview
- 8.8.3 Pfizer Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Pfizer Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.8.5 Pfizer Recent Developments
- 8.9 Jiangsu Hengrui Pharmaceuticals
- 8.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 8.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 8.9.3 Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Jiangsu Hengrui Pharmaceuticals Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 8.10 GlaxoSmithKline
- 8.10.1 GlaxoSmithKline Company Information
- 8.10.2 GlaxoSmithKline Business Overview
- 8.10.3 GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 GlaxoSmithKline Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.10.5 GlaxoSmithKline Recent Developments
- 8.11 AstraZeneca
- 8.11.1 AstraZeneca Company Information
- 8.11.2 AstraZeneca Business Overview
- 8.11.3 AstraZeneca Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 AstraZeneca Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.11.5 AstraZeneca Recent Developments
- 8.12 Viatris
- 8.12.1 Viatris Company Information
- 8.12.2 Viatris Business Overview
- 8.12.3 Viatris Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Viatris Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.12.5 Viatris Recent Developments
- 8.13 Boehringer Ingelheim
- 8.13.1 Boehringer Ingelheim Company Information
- 8.13.2 Boehringer Ingelheim Business Overview
- 8.13.3 Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Boehringer Ingelheim Anti-Asthma Short Acting Beta Agonists Product Portfolio
- 8.13.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-Asthma Short Acting Beta Agonists Value Chain Analysis
- 9.1.1 Anti-Asthma Short Acting Beta Agonists Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-Asthma Short Acting Beta Agonists Production Mode & Process
- 9.2 Anti-Asthma Short Acting Beta Agonists Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-Asthma Short Acting Beta Agonists Distributors
- 9.2.3 Anti-Asthma Short Acting Beta Agonists Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst